Arcadia Biosciences Inc. (NASDAQ: RKDA) is 7.11% higher on its value in year-to-date trading and has touched a low of $2.26 and a high of $6.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RKDA stock was last observed hovering at around $2.62 in the last trading session, with the day’s gains setting it 0.09% off its average median price target of $7.53 for the next 12 months. It is also 70.06% off the consensus price target high of $9.05 offered by 1 analysts, but current levels are 54.83% higher than the price target low of $6.00 for the same period.
Currently trading at $2.71, the stock is -2.25% and -12.68% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.71 million and changing 3.44% at the moment leaves the stock -15.10% off its SMA200. RKDA registered -7.82% loss for a year compared to 6-month loss of -9.97%. The firm has a 50-day simple moving average (SMA 50) of $2.9066 and a 200-day simple moving average (SMA200) of $3.0327.
The stock witnessed a -6.55% gain in the last 1 month and extending the period to 3 months gives it a 4.63%, and is -1.63% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.11% over the week and 8.29% over the month.
Arcadia Biosciences Inc. (RKDA) has around 41 employees, a market worth around $58.16M and $1.30M in sales. Distance from 52-week low is 19.91% and -57.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.00%).
Arcadia Biosciences Inc. (RKDA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Arcadia Biosciences Inc. (RKDA) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Arcadia Biosciences Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.29 with sales reaching $1.75M over the same period.The EPS is expected to shrink by -70.20% this year, but quarterly earnings will post 36.00% year-over-year. Quarterly sales are estimated to grow 466.30% in year-over-year returns.
Arcadia Biosciences Inc. (RKDA) Top Institutional Holders
24 institutions hold shares in Arcadia Biosciences Inc. (RKDA), with 1.64M shares held by insiders accounting for 7.70% while institutional investors hold 8.88% of the company’s shares. The shares outstanding are 11.12M, and float is at 10.51M with Short Float at 10.06%. Institutions hold 8.20% of the Float.
The top institutional shareholder in the company is Ardsley Advisory Partners with over 0.3 million shares valued at $0.76 million. The investor’s holdings represent 1.41% of the RKDA Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 0.26 million shares valued at $0.67 million to account for 1.24% of the shares outstanding. The other top investors are Susquehanna International Group, LLP which holds 0.18 million shares representing 0.85% and valued at over $0.46 million, while Gsa Capital Partners Llp holds 0.60% of the shares totaling 0.13 million with a market value of $0.32 million.
Arcadia Biosciences Inc. (RKDA) Insider Activity
A total of 0 insider transactions have happened at Arcadia Biosciences Inc. (RKDA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Plavan Matthew T ,the company’sChief Executive Officer. SEC filings show that Plavan Matthew T bought 585 shares of the company’s common stock on Aug 03 at a price of $3.16 per share for a total of $1849.0. Following the purchase, the insider now owns 14285.0 shares.
Arcadia Biosciences Inc. disclosed in a document filed with the SEC on Aug 03 that Shultz Randall (Chief Technology Officer) bought a total of 700 shares of the company’s common stock. The trade occurred on Aug 03 and was made at $3.16 per share for $2212.0. Following the transaction, the insider now directly holds 13000.0 shares of the RKDA stock.
Still, SEC filings show that on Aug 03, Haley Pamela (Chief Financial Officer) acquired 700 shares at an average price of $3.16 for $2212.0. The insider now directly holds 2,638 shares of Arcadia Biosciences Inc. (RKDA).